On Friday, Shares of Pandora Media Inc (NYSE:P), lost -0.65% to $13.73.
Pandora, declared that the company’s Chief Financial Officer, Mike Herring, and Vice President, Dominic Paschel, will present at the Credit Suisse 19th Annual Technology, Media & Telecom Conference, the Raymond James TMT Conference, and the Wedbush 2015 California Dreamin’ Technology, Consumer Administration Access Conference.
Mr. Herring will engage in a fireside chat at the Credit Suisse 19th Annual Technology, Media & Telecom Conference on Wednesday, December 2, 2015 at 10:30 a.m. MT / 12:30 p.m. ET in Scottsdale, AZ.
Mr. Paschel will engage in a fireside chat at the Raymond James TMT Conference on Tuesday, December 8, 2015 at 6:35 a.m. PT / 9:35 a.m. ET in New York, NY.
Mr. Herring will engage in a fireside chat at the Wedbush 2015 California Dreamin’ Technology, Consumer Administration Access Conference on Thursday, December 10, 2015 at 9:10 a.m. PT / 12:10 p.m. ET in Santa Monica, CA.
Pandora Media, Inc. provides Internet radio services in the United States. The company allows listeners to create up to 100 personalized stations to access free music and comedy catalogs, in addition to offers Pandora One, a paid subscription service to listeners.
Shares of Ascent Solar Technologies, Inc. (NASDAQ:ASTI), inclined 0.74% to $0.123, during its last trading session.
Ascent Solar Technologies, declared that the Company has reached an amendment agreement (“Agreement”) with its existing senior secured note holder (“Note Holder”) to further restructure the outstanding senior secured convertible notes (“Outstanding Notes”).
Following the Agreement, the Company has now agreed to (i) make a cash payment of $1.0 million to the Note Holder on December 21, 2015 in lieu of the original payable amount of $2.8 million, and (ii) reinstate the $1.8 million portion of the Outstanding Notes with substantially all of its current and existing conversion rights and terms (“Reinstated Notes”). As part of the amendment, the Note Holder has agreed to waive the true-up provision contained in such Reinstated Notes. Hence, the Company will not be required to issue any additional shares of common stock after any portions of the Reinstated Notes are converted at the applicable conversion price.
The Note Holder has also agreed to release, as of January 15, 2016, the security interest on the accounts receivable of the Company that constituted a portion of the collateral securing the Outstanding Notes, and to fully release as of February 8, 2016, the security interest in the remaining collateral securing the Outstanding Notes.
Ascent Solar Technologies, Inc., a development stage company, designs and manufactures photovoltaic integrated consumer electronics; and portable power applications for commercial and military users.
Finally, Shares of EXACT Sciences Corporation (NASDAQ:EXAS), ended its last trade with 3.82% gain, and closed at $9.23.
The Centers for Medicare and Medicaid Services (CMS) posted the 2016 Clinical Diagnostic Laboratory Fee Plan (CLFS) on its website. The reimbursement national limitation amount (NLA) for Cologuard within the 2016 CLFS appears to be inconsistent with what CMS publicly communicated on November 17, 2015, when issuing a final reimbursement decision for Cologuard using the crosswalk methodology to CPT codes 81315, 81275, and 82274. Based on the 2016 CLFS as posted, the sum of the NLAs for those three codes is $501.26.
Last year, the NLA for Cologuard in the 2015 CLFS, as initially posted on the CMS website, was significantly lower than the sum of the NLAs for the three codes to which Cologuard is cross-walked. CMS subsequently issued a correction to the 2015 CLFS and ultimately established an NLA for Cologuard of $492.72.
Exact Sciences requested that CMS clarify the 2016 reimbursement rate for Cologuard. Exact Sciences will communicate more information as it becomes available.
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing non-invasive colorectal cancer screening products. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer.